

Special Issue

Identification of Candidate Genes in Breast and Ovarian Cancer

Message from the Guest Editors

On a global scale, breast cancer is the most frequently diagnosed cancer in women; there were over 2 million new cases in 2018, contributing to about 11.6% of the total cancer incidence burden (Globocan 2018, International Agency for Research on Cancer). However, although the last decade has seen an increase in breast cancer incidence, there have also been great improvements in its diagnosis and survival with nearly 80% of breast cancer patients surviving for at least 10 years (Cancer Research UK). According to the International Agency for Research on Cancer, in 2018, female breast cancer ranked as the fifth leading cause of death (627,000 deaths, 6.6%) due to the prognosis being relatively favourable, at least in more developed countries. Novel therapeutics, such as Herceptin (trastuzumab), and hormone-related biological therapies have greatly contributed to the increased survival rate, as has the knowledge acquired in cancer biology, particularly regarding the identification of candidate genes using molecular and computational approaches to interpret the “OMICs” big data generated principally by genomics and transcriptomics.

Guest Editors

Dr. Nadège Presneau
Prof. BIGNON Yves-Jean
Dr. Pinar Uysal-Onganer

Deadline for manuscript submissions

closed (31 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/43230

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)